The positive final overall survival data from the NORA study of ZEJULA in platinum-sensitive recurrent ovarian cancer is significant for Zai Lab. This data reinforces ZEJULA's position as a leading PARP inhibitor for ovarian cancer maintenance therapy in China, potentially enhancing Zai Lab's market share and reputation in oncology. The absence of new safety signals and the drug's approval for various maintenance settings could lead to increased adoption and sales, positively impacting ZLAB's stock in the short term.